About ARS Pharmaceuticals
ARS Pharmaceuticals is a publicly listed company based in San Diego (United States) founded in 2018. ARS Pharmaceuticals has raised $75 million across 2 funding rounds from investors including RA Capital, SR One and Deerfield. The company has 160 employees. Its website ars-pharma.com draws about 28 thousand monthly visits. ARS Pharmaceuticals offers products and services including neffy and neffyConnect. Its focus areas include Life Sciences, Immunology, Drugs and Allergies. Its legal entity is ARS Pharmaceuticals, Inc. Its competitors include Dren Bio, PureTech Health and TORL BioTherapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutics for the treatment of allergic reactions. The company has developed an epinephrine nasal spray ARS-1 which is uniquely formulated with absorption enhancing technology used for the treatment of anaphylaxis.
- Headquarters San Diego, United States
- Employees 160
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website ars-pharma.com
- Social LinkedIn X
- Legal Name Ars Pharmaceuticals, Inc.
- Annual Revenue$84.28 M (USD)-5.46as on Dec 31, 2025
- Net Profit-$171.3 M (USD)-2241.76as on Dec 31, 2025
- EBITDA-$178.08 M (USD)-6094.12as on Dec 31, 2025
- Total Equity Funding$75M (USD)
in 2 rounds
- Latest Funding Round$55M (USD), Series D
Aug 2021
- InvestorsRA Capital
& 2 more
- Employee Count160
Products & Services of ARS Pharmaceuticals
ARS Pharmaceuticals offers a comprehensive portfolio of products and services, including neffy and neffyConnect.
FDA-approved needle-free treatment for severe allergic reactions.
Resource platform for patients accessing epinephrine therapies.
Funding Insights of ARS Pharmaceuticals
ARS Pharmaceuticals has successfully raised a total of $75M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $55 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $75M
- Total Rounds 2
- Last Round Series D — $55M
- First Round $20M
(Dec 2018)
- Investors Count 3
All 2 funding rounds of ARS Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in ARS Pharmaceuticals
ARS Pharmaceuticals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, SR One and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for ARS Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ARS Pharmaceuticals
33 people are tracked at ARS Pharmaceuticals (19 in leadership, 11 in board & advisors, 3 in team); the tracked headcount is 160.
| Name | Role | Group |
|---|---|---|
Justin Chakma | Chief Business Officer | Leadership |
Sarina Tanimoto | Co-Founder & Chief Medical Officer | Leadership |
Richard Lowenthal | Co-Founder, President & CEO | Leadership |
Robert Bell | Co-Founder & Chief Science Officer | Leadership |
Chris Kyle | Executive Director, Associate General Counsel | Leadership |
Lynda Harris | Vice President/head Of Human Resources | Leadership |
Denny Maula | Associate Director, Contracts & Sr. Paralegal | Leadership |
Kristin Wills, MBA | Senior Director of Accounting | Leadership |
Kathleen Scott | CFO | Leadership |
Lisa Clark | Director of Talent Acquisition & Human Resources | Leadership |
Brian T. Dorsey | Chief Operating Officer | Leadership |
Alexander A. Fitzpatrick | Chief Legal Officer | Leadership |
Nick Rueb, CPA, MSA | Director, SEC Reporting and Technical Accounting | Leadership |
Alex Fitzpatrick | Chief Legal Officer | Leadership |
Andrew Alwood | VP of Finance | Leadership |
Ayman R. Kafal | Vice President, Head Of Medical Affairs | Leadership |
Darrin Bryan | VP Analytics & Commercial Operations | Leadership |
Eric Karas | Chief Commercial Officer | Leadership |
Christine Cuellar | Executive Director / Head Of Quality Assurance | Leadership |
Peter A. Thompson | Board Member | Board & advisors |
13 more people are available in the full profile.
Complete people profiles for ARS Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ARS Pharmaceuticals
ARS Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol SPRY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Sep 2022
- Listed onNASDAQ: SPRY
- Listed entityARS Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS82835W1080
- Share price$4.05 (-3.11% on the day) · 2026-10-13
- Market capitalisation$402.8M
- EPS (diluted, trailing year)$-2.17
- Volume (last session)1,546,825
Financials of ARS Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $84.3M | -$171.3M | -$178.1M |
| 2024 | $89.2M | $8.0M | -$2.9M |
| 2023 | $30,000 | -$54.4M | -$67.5M |
| 2022 | $1.3M | -$34.7M | -$35.2M |
| 2021 | $5.5M | -$20.2M | -$19.2M |
Detailed financial statements for ARS Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ARS Pharmaceuticals
4 dated milestones of ARS Pharmaceuticals across 4 years, from founding to its latest funding, stage changes and deals.
- Founded ARS Pharmaceuticals is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series D, of $55.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of ARS Pharmaceuticals
ARS Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Dren Bio, PureTech Health and TORL BioTherapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| drenbio.com | 2019 | San Carlos, United States | $131M | Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases. | ||
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| torlbio.com | 2019 | Los Angeles, United States | $412.3M | Antibody-based therapeutics are developed for cancer treatment. |
Detailed competitors of ARS Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ARS Pharmaceuticals
The website of ARS Pharmaceuticals (ars-pharma.com) receives about 27.7K visits a month and ranks #909,122 among all websites worldwide, #1,088 in Biotechnology and Pharmaceuticals.
- Monthly visits27.7K
▼ 6.5% vs previous month
- Unique visitors10.8K
per month
- Global rank#909,122
among all websites
- Category rank#1,088
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit2.6
- Average visit55 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with ARS Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
neffy.com | neffy.com | 100% | #431,841 | – | |
| allergicliving.com | 94% | #548,253 | View details | ||
| pharmabiz.com | 83% | #665,634 | View details | ||
thepharmaletter.com | thepharmaletter.com | 82% | #486,864 | – | |
| pharmacytimes.com | 80% | 495.5K | #125,424 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for ARS Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as ARS Pharmaceuticals (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ars Pharmaceuticals
Complete news archive for ARS Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ARS Pharmaceuticals
ARS Pharmaceuticals was founded in 2018.
ARS Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
ARS Pharmaceuticals is a funded company, having raised a total of $75M across 2 funding rounds to date. The company's 1st funding round was a Series C of $20M, raised on Dec 2018.
ARS Pharmaceuticals has 160 employees.
Annual revenue of ARS Pharmaceuticals is $84.28M as on Dec 31, 2025.
Developer of therapeutics for the treatment of allergic reactions. The company has developed an epinephrine nasal spray ARS-1 which is uniquely formulated with absorption enhancing technology used for the treatment of anaphylaxis.
ARS Pharmaceuticals's top competitors include Dren Bio, PureTech Health and TORL BioTherapeutics.
ARS Pharmaceuticals offers neffy and neffyConnect.
Yes, ARS Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol SPRY.
ARS Pharmaceuticals has 3 investors. Key investors include RA Capital, SR One, and Deerfield.
ARS Pharmaceuticals operates through Ars Pharmaceuticals, Inc..